as 11-07-2025 3:52pm EST
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | MIDDLETOWN |
| Market Cap: | 1.2B | IPO Year: | 2017 |
| Target Price: | $22.00 | AVG Volume (30 days): | 889.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.03 - $19.98 | Next Earning Date: | 11-06-2025 |
| Revenue: | $134,481,000 | Revenue Growth: | 116.21% |
| Revenue Growth (this year): | 99.52% | Revenue Growth (next year): | -0.28% |
ZYME Breaking Stock News: Dive into ZYME Ticker-Specific Updates for Smart Investing
Zacks
a day ago
GlobeNewswire
a day ago
Zacks
4 days ago
Simply Wall St.
4 days ago
Zacks
9 days ago
Zacks
10 days ago
GlobeNewswire
11 days ago
Simply Wall St.
4 months ago
The information presented on this page, "ZYME Zymeworks Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.